HUBUC Launches P1, a global card issuing and processing engine, becoming a Mastercard Network Enablement Partner
15.2.2023 10:07:00 EET | Business Wire | Press release
Leading fintech company HUBUC announces the immediate availability of its revolutionary issuing processor, a Mastercard-certified platform that makes card issuing easier than ever.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230213005527/en/
HUBUC Founders, Ignacio Javierre and Hasan Nawaz (Photo: Business Wire)
The platform has global scalability and plug-and-play connectivity at its core, allowing financial institutions and fintechs to enhance their customer experiences and deploy disruptive payment card use cases in a matter of weeks.
HUBUC decided to build P1, a new issuing processor in-house when existing ones proved to be running on legacy technology from the 1960's and provided outdated functionalities.
HUBUC's commitment with P1 is to bring lightning-fast performance, lean implementation and microservices architecture that allows scalability and innovation for years to come.
The cloud-based platform has key capabilities such as card-level spending controls, regulatory issuer reporting, cloud processing for scalability and comes with a stellar developer experience with Public Sandbox and OpenAPI specification.
Additionally, the platform offers strong customer authentication for enhanced security against fraud, and is GDPR, PSD2 and PCI DSS 3.2 Level 1 compliant.
The platform’s powerful issuing processor is the ultimate infrastructure to innovate with a Mastercard product and generate new revenue streams, improve unit economics and become a leading company in any sector.
P1 customers like Coverflex are an example of how to leverage HUBUC services. Coverflex’s solution allows a company to design more bespoke employee compensation, such as health insurance, meal allowance, fringe benefits and discounts, by aggregating multiple providers. This year Coverflex recently raised €15 million Series A, to keep increasing their existing customer base of 3,600+ companies, including Santander, Natixis, OysterHR, Bolt, Emma, Revolut and Smartex.
In a statement, Coverflex CEO Miguel Amaro said: “At Coverflex, we are dedicated to providing cutting-edge employee benefits via a smart card to our clients in Europe. Our focus on increasing the unit economics and scalability of our card product has been a top priority, and we are thrilled to announce that our partnership with HUBUC has enabled us to achieve this goal. Working with industry leaders like Ignacio and Hasan has been a truly enlightening experience, allowing us to expand our knowledge and understanding of the payments world. This collaboration has allowed us to significantly enhance our proposition to our clients, delivering increased efficiency and a better user experience for our cardholders.”
HUBUC's leadership team has been innovating in the fintech industry for years and brings experience building financial infrastructure across Europe to scale it globally.
HUBUC is backed by some of the best venture capitalists and operators in the industry, such as Y Combinator, Jeffrey Katzenberg (Managing Partner at WndrCo, Former Chairman Walt Disney Studios and DreamWorks Animations), Runa Capital, Village Global, Eric Yuan (Zoom), John Lilly (Mozilla), Immad Akhund (Mercury), John Bautista (Orrick), Charles Delingpole (ComplyAdvantage) among others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230213005527/en/
Contact information
HUBUC Inc.
press@hubuc.com | Ignacio Javierre
https://www.hubuc.com/about-us
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom